Could common statins be a surprise weapon against brittle bones?
NCT ID NCT07717788
First seen Jul 21, 2026 · Last updated Jul 22, 2026 · Updated 1 time
Summary
This study looks at whether adding a statin (atorvastatin or rosuvastatin) to standard osteoporosis treatment can improve bone density in postmenopausal women. Participants are women aged 55 and older with osteoporosis who also have high cholesterol. The trial compares standard therapy alone versus standard therapy plus one of the two statins, measuring changes in bone density and bone turnover markers over six months.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- atorvastatin and rosuvastatin, added to standard osteoporosis therapy (alendronate, calcium, vitamin D)
- What this could lead to
- If statins help build bone, this could point to a dual-purpose treatment for postmenopausal women with both high cholesterol and osteoporosis.
- What could go wrong
- This is a small, early-stage study with only 65 participants. Statins are not proven to treat osteoporosis, and any bone benefits may be modest or absent.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Not a phased trial
Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.
- Participants
-
65 people
The number who actually took part.
- Started
-
Feb 2025
- Finished
-
Jul 2026
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
55 years and older
- Sex
-
Female participants only
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * patients aged ≥ 55 diagnosed with primary age-related osteoporosis according to European guidance osteoporosis, T-score ≤-2.5, and did not receive any treatment for osteoporosis previously or statins. Exclusion Criteria: * patients who had been taking antiresorptive, bone forming or statins, patients who were taking any medications that can affect osteoporosis. Patients who had medical issues that could be a secondary cause for osteoporosis. and patients who were allergic to alendronate or statins were excluded from the study.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Osteoporosis are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
AL-KUFA UNIVERSITY/College of Pharmacy
Najaf, Iraq
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can better posture strengthen the pelvic floor in osteoporosis?
- Could exercise be the key to stronger bones in women?
- Robotic legs may help rebuild bone in people with spinal cord injury
- Could a simple education program stop the cycle of fractures in the elderly?
- Could cannabis oil be a new key to chronic pain relief and stronger bones in women?
- Could lipedema weaken bones? a new study investigates